Last reviewed · How we verify
NCT04776083
Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients
Phase 3 trial testing first line systemic therapy in Non-Small Cell Carcinoma of Lung, TNM Stage 4 in 75 participants. Completed in 25 November 2023.
25 November 2023
Quick facts
| Lead sponsor | Menoufia University |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 25 September 2020 |
| Primary completion | 25 November 2023 |
| Estimated completion | 25 November 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- first line systemic therapy — full drug profile →
- 3D radiotherapy or IMRT
Conditions studied
- Non-Small Cell Carcinoma of Lung, TNM Stage 4 — all drugs for Non-Small Cell Carcinoma of Lung, TNM Stage 4 →
- Radiation Therapy — all drugs for Radiation Therapy →
Sponsor
Menoufia University
Who can join
Eligibility, any sex, with Non-Small Cell Carcinoma of Lung, TNM Stage 4 or Radiation Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
study the effect of radiotherapy to the primary lesion after first line systemic therapy in metastatic non-small cell lung cancer patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04776083
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Small Cell Carcinoma of Lung, TNM Stage 4
Currently open trials in the same condition.
- NCT03774732 — PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cance · Phase 3 · active not recruiting
- NCT03042221 — Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy · recruiting
Other Menoufia University trials
Trials by the same sponsor.
- NCT07522671 — Clinical Performance of 3D-Printed Resin and Zirconia Implant Restorations · NA · recruiting
- NCT07516236 — Dynamic SvO2 in Predicting Fluid Responsiveness in Septic Shock · not yet recruiting
- NCT07485517 — Deep Versus Moderate Neuromuscular Blocking · NA · recruiting
- NCT07506044 — Dexmedetomidine as an Adjuvant During Dural Puncture Epidural · NA · recruiting
- NCT07322471 — Efficacy and Safety of Flexible Ureteroscopy Versus Percutaneous Nephrolithotomy in Management of Staghorn Stones · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04776083 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Menoufia University
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04776083.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing